Xtant Medical (NYSEAMERICAN:XTNT) Receives Buy Rating from BTIG Research

Posted by on May 13th, 2026

Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $1.00 target price on the medical device company’s stock. BTIG Research’s target price would suggest a potential upside of 112.63% from the stock’s current price.

Separately, Craig Hallum restated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1.00.

Check Out Our Latest Report on Xtant Medical

Xtant Medical Trading Down 6.8%

Shares of NYSEAMERICAN:XTNT traded down $0.03 during trading on Wednesday, reaching $0.47. 263,189 shares of the stock were exchanged, compared to its average volume of 158,835. Xtant Medical has a 12-month low of $0.44 and a 12-month high of $0.95. The firm’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.64. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.63 and a current ratio of 2.65. The firm has a market cap of $65.87 million, a price-to-earnings ratio of 15.68 and a beta of -0.11.

Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last issued its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). Xtant Medical had a return on equity of 10.27% and a net margin of 3.71%.The company had revenue of $20.88 million during the quarter, compared to the consensus estimate of $20.16 million.

Hedge Funds Weigh In On Xtant Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC lifted its position in shares of Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after acquiring an additional 57,000,000 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 205,945 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Xtant Medical in the fourth quarter valued at $284,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Xtant Medical in the fourth quarter valued at $220,000. 69.33% of the stock is owned by institutional investors.

About Xtant Medical

(Get Free Report)

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.

Featured Stories

Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.